Peter Openshaw
Questions over AstraZeneca's Covid-19 vaccine data risk delaying approval
Days after grabbing headlines with its Covid-19 "vaccine for the world," AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting speedy US and EU regulatory approval.